Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib

Keizman D., Sarid D., Lee J. L. , Sella A., Gottfried M., Hammers H., ...More

ONCOLOGIST, vol.21, no.10, pp.1212-1217, 2016 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 21 Issue: 10
  • Publication Date: 2016
  • Doi Number: 10.1634/theoncologist.2015-0428
  • Title of Journal : ONCOLOGIST
  • Page Numbers: pp.1212-1217


Background. Sunitinib is a standard treatment for metastatic clear cell renal cell carcinoma (mccRCC). Data on its activity in the rare variant of metastatic chromophobe renal cell carcinoma (mchRCC), are limited. We aimed to analyze the activity of sunitinib in a relatively large and homogenous international cohort of mchRCC patients in terms of outcome and comparison with mccRCC.